Incidentally, Grb2 SH2 domain-binding antagonists were shown in vitro to block HGF-induced migration and invasion in MDCK epithelial cells, metastasis formation of melanoma and prostate cancer cells in vivo, and the motility of human SW620 CRC cells in wound-healing in vitro assays [61-63]. This evidence concerns the gene HGF and prostate carcinoma.